Mechanistic Insights into PRRSV Inhibition through CD163-SRCR5 Blockade by PRRSV/CD163-IN-1
1
Issued Date
2025-01-01
Resource Type
eISSN
19487185
Scopus ID
2-s2.0-105008377729
Journal Title
Journal of Physical Chemistry Letters
Start Page
6286
End Page
6292
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Physical Chemistry Letters (2025) , 6286-6292
Suggested Citation
Thitayanuwat P., Hengphasatporn K., Chankhamhaengdecha S., Shigeta Y. Mechanistic Insights into PRRSV Inhibition through CD163-SRCR5 Blockade by PRRSV/CD163-IN-1. Journal of Physical Chemistry Letters (2025) , 6286-6292. 6292. doi:10.1021/acs.jpclett.5c01528 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/110920
Title
Mechanistic Insights into PRRSV Inhibition through CD163-SRCR5 Blockade by PRRSV/CD163-IN-1
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) causes severe economic losses in the swine industry by targeting pulmonary alveolar macrophages via the CD163 receptor, particularly its SRCR5 domain. However, the molecular details of small-molecule inhibition at this interface remain unclear. Here, we provide the first mechanistic insights into how the PRRSV/CD163-IN-1 (B7) compound blocks CD163-SRCR5. Using structural refinement, molecular dynamics (MD) simulations, ensemble docking, and fragment molecular orbital (FMO) calculations, we identified a plausible B7/CD163-SRCR5 binding conformation. Due to the limitations of the crystal structure in representing conformational flexibility, we proposed an MD-refined model of CD163-SRCR5 to facilitate the efficient virtual screening of a small-molecule repurposing library. Baicalin emerged as a top candidate through the in silico analyses, consistent with previous experimental evidence. This result supports baicalin’s antiviral activity, reinforcing its potential as a lead compound. This study provides a molecular basis for ligand recognition at CD163-SRCR5 and a framework for designing PRRSV entry inhibitors.